• Users Online: 321
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 14  |  Issue : 1  |  Page : 16-20

Detection of Heteroresistant Vancomycin-Intermediate Staphylococcus aureus among Methicillin-Resistant Staphylococcus aureus


1 Department of Microbiology, Santosh Medical College and Hospital, Santosh Deemed to be University, Ghaziabad, Uttar Pradesh, India
2 Department of Microbiology, Maharishi Markandeshwar Medical College and Hospital, Maharishi Markandeshwar University, Solan, Himachal Pradesh, India

Correspondence Address:
Dakshina Bisht
Department of Microbiology, Santosh Medical College and Hospital, Santosh Deemed to be University, Ghaziabad - 201 009, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ajprhc.ajprhc_14_21

Rights and Permissions

Background: The testing of heteroresistance vancomycin-intermediate Staphylococcus aureus (hVISA) by the population analysis profile-area under the curve (PAP-AUC) is tedious and laborious. The goal of this study was to determine the prevalence of hVISA among methicillin-resistant S. aureus (MRSA) and compare two screening tests: brain heart infusion agar with vancomycin 4 mg/L (BHIV4) and macromethod E-test (MET) with PAP-AUC as the gold standard. Materials and Methods: Antibiotic sensitivity test and detection of MRSA were performed according to the CLSI guidelines. PAP-AUC, BHIV4, and MET were used to detect hVISA. Results: A total of 288 MRSA isolates were tested for hVISA, with 48 (16.66%) being detected by PAP-AUC. With PAP-AUC, BHIV4's sensitivity, specificity, positive predictive value, and negative predictive value were 70.83%, 96.66%, 80.95%, and 94.3%, respectively. The majority of hVISA isolates were found in the vancomycin minimum inhibitory concentration range 1–2 mg/L. Conclusions: hVISA was found to be 16.6% in this investigation. When compared to MET, BHIV4 had a higher sensitivity, and teicoplanin and linezolid were found to be the most effective drug against hVISA.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1658    
    Printed163    
    Emailed0    
    PDF Downloaded144    
    Comments [Add]    

Recommend this journal